ArticleArteriosclerosis, thrombosis, and vascular biology2010
Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Endothelial TRIM35-Regulated MMP10 Release Exacerbates Calcification of Vascular Grafts.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?Nature reviews. Cardiology · 2022Review
- Current advances in the imaging of atherosclerotic vulnerable plaque using nanoparticles.Materials today. Bio · 2022Review
- Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method.International journal of molecular sciences · 2022Article
- Development and Validation of an HPLC-MS/MS Method for Pioglitazone from Nanocarriers Quantitation in Ex Vivo and In Vivo Ocular Tissues.Pharmaceutics · 2021Article
- Macrophage targeted theranostic strategy for accurate detection and rapid stabilization of the inflamed high-risk plaque.Theranostics · 2021Article
- Atorvastatin ReducesJournal of the American Society of Nephrology : JASN · 2020Article
- Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.International journal of molecular sciences · 2020Article
- Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT.Korean circulation journal · 2018Article
- Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm.JCI insight · 2018Article
- An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm.Nature communications · 2018Article
- Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo.Theranostics · 2018Article
- A novel polymer-free ciglitazone-coated vascular stent: in vivo and ex vivo analysis of stent endothelialization in a rabbit iliac artery model.Oncotarget · 2016Article
- Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring.PloS one · 2015Article
- The advancing clinical impact of molecular imaging in CVD.JACC. Cardiovascular imaging · 2013Review
- High-resolution optical mapping of inflammatory macrophages following endovascular arterial injury.Molecular imaging and biology · 2013Article
- High-resolution molecular imaging via intravital microscopy: illuminating vascular biology in vivo.Integrative biology : quantitative biosciences from nano to macro · 2013Review
- Article
- Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging.Arteriosclerosis, thrombosis, and vascular biology · 2012Article
- Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.Circulation research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the effects of pioglitazone (PIO), a peroxisome proliferator-activated receptor γ agonist, on plaque matrix metalloproteinase (MMP) and macrophage (Mac) responses in vivo in a molecular imaging study. METHODS AND
resultsIn vitro, PIO suppressed MMP-9 protein expression in murine peritoneal Macs (P<0.05). To assess PIO's effects on plaque inflammation, nondiabetic apolipoprotein E(-/-) mice receiving a high-cholesterol diet (HCD) were administered an MMP-activatable fluorescence imaging agent and a spectrally distinct Mac-avid fluorescent nanoparticle. After 24 hours, mice underwent survival dual-target intravital fluorescence microscopy of carotid arterial plaques. These mice were then randomized to HCD or HCD plus 0.012% PIO for 8 weeks, followed by a second intravital fluorescence microscopy study of the same carotid plaque. In the HCD group, in vivo MMP and Mac target-to-background ratios increased similarly (P<0.01 versus baseline). In contrast, PIO reduced MMP and Mac target-to-background ratios (P<0.01) versus HCD. Changes in MMP and Mac signals correlated strongly (r ≥0.75). Microscopy demonstrated MMP and Mac reductions in PIO-treated mice and a PIO-modulated increase in plaque collagen.
conclusionsSerial optical molecular imaging demonstrates that plaque MMP and Mac activity in vivo intensify with hypercholesterolemia and are reduced by PIO therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.